Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 142

1.

Characterization of the protective borreliacidal antibody response in humans and hamsters after vaccination with a Borrelia burgdorferi outer surface protein A vaccine.

Padilla ML, Callister SM, Schell RF, Bryant GL, Jobe DA, Lovrich SD, DuChateau BK, Jensen JR.

J Infect Dis. 1996 Oct;174(4):739-46.

PMID:
8843211
2.

Occurrence of severe destructive lyme arthritis in hamsters vaccinated with outer surface protein A and challenged with Borrelia burgdorferi.

Croke CL, Munson EL, Lovrich SD, Christopherson JA, Remington MC, England DM, Callister SM, Schell RF.

Infect Immun. 2000 Feb;68(2):658-63.

3.

Vaccination against lyme disease with recombinant Borrelia burgdorferi outer-surface protein A (rOspA) in horses.

Chang Y, Novosol V, McDonough SP, Chang CF, Jacobson RH, Divers T, Quimby FW, Shin S, Lein DH.

Vaccine. 1999 Oct 14;18(5-6):540-8.

PMID:
10519945
4.
5.

Ability of canine Lyme disease vaccine to protect hamsters against infection with several isolates of Borrelia burgdorferi.

Jobe DA, Callister SM, Lim LC, Lovrich SD, Schell RF.

J Clin Microbiol. 1994 Mar;32(3):618-22.

6.

Inhibition of the production of anti-OspA borreliacidal antibody with T cells from hamsters vaccinated against Borrelia burgdorferi.

Jensen JR, Du Chateau BK, Munson EL, Callister SM, Schell RF.

Infect Immun. 1998 Apr;66(4):1507-12.

7.

Specific immune response to a synthetic peptide derived from outer surface protein C of Borrelia burgdorferi predicts protective borreliacidal antibodies.

Ikushima M, Matsui K, Yamada F, Kawahashi S, Nishikawa SK.

FEMS Immunol Med Microbiol. 2000 Sep;29(1):15-21.

8.

Characterization of the borreliacidal antibody response to Borrelia burgdorferi in humans: a serodiagnostic test.

Callister SM, Schell RF, Case KL, Lovrich SD, Day SP.

J Infect Dis. 1993 Jan;167(1):158-64.

PMID:
8418162
9.

Recombinant OspA protects dogs against infection and disease caused by Borrelia burgdorferi.

Chang YF, Appel MJ, Jacobson RH, Shin SJ, Harpending P, Straubinger R, Patrican LA, Mohammed H, Summers BA.

Infect Immun. 1995 Sep;63(9):3543-9.

10.

Production of borreliacidal antibody to outer surface protein A in vitro and modulation by interleukin-4.

Munson EL, Du Chateau BK, Jobe DA, Lovrich SD, Callister SM, Schell RF.

Infect Immun. 2000 Oct;68(10):5496-501.

11.

Borreliacidal OspC antibodies specific for a highly conserved epitope are immunodominant in human lyme disease and do not occur in mice or hamsters.

Lovrich SD, Jobe DA, Schell RF, Callister SM.

Clin Diagn Lab Immunol. 2005 Jun;12(6):746-51. Erratum in: Clin Diagn Lab Immunol. 2005 Sep;12(9):1139.

12.

Detection of multiple reactive protein species by immunoblotting after recombinant outer surface protein A lyme disease vaccination.

Molloy PJ, Berardi VP, Persing DH, Sigal LH.

Clin Infect Dis. 2000 Jul;31(1):42-7. Epub 2000 Jul 17.

PMID:
10913394
14.

A recombinant vaccine for Lyme disease.

Wallich R, Kramer MD, Simon MM.

Behring Inst Mitt. 1994 Dec;(95):106-8. Review.

PMID:
7755503
15.

Reactivity with a specific epitope of outer surface protein A predicts protection from infection with the Lyme disease spirochete, Borrelia burgdorferi.

Golde WT, Piesman J, Dolan MC, Kramer M, Hauser P, Lobet Y, Capiau C, Desmons P, Voet P, Dearwester D, Frantz JC.

Infect Immun. 1997 Mar;65(3):882-9.

16.

Vaccination against Lyme disease with recombinant Borrelia burgdorferi outer-surface lipoprotein A with adjuvant. Lyme Disease Vaccine Study Group.

Steere AC, Sikand VK, Meurice F, Parenti DL, Fikrig E, Schoen RT, Nowakowski J, Schmid CH, Laukamp S, Buscarino C, Krause DS.

N Engl J Med. 1998 Jul 23;339(4):209-15.

17.

Safety and immunogenicity of recombinant Bacille Calmette-Guérin (rBCG) expressing Borrelia burgdorferi outer surface protein A (OspA) lipoprotein in adult volunteers: a candidate Lyme disease vaccine.

Edelman R, Palmer K, Russ KG, Secrest HP, Becker JA, Bodison SA, Perry JG, Sills AR, Barbour AG, Luke CJ, Hanson MS, Stover CK, Burlein JE, Bansal GP, Connor EM, Koenig S.

Vaccine. 1999 Feb 26;17(7-8):904-14.

PMID:
10067697
18.

A vaccine consisting of recombinant Borrelia burgdorferi outer-surface protein A to prevent Lyme disease. Recombinant Outer-Surface Protein A Lyme Disease Vaccine Study Consortium.

Sigal LH, Zahradnik JM, Lavin P, Patella SJ, Bryant G, Haselby R, Hilton E, Kunkel M, Adler-Klein D, Doherty T, Evans J, Molloy PJ, Seidner AL, Sabetta JR, Simon HJ, Klempner MS, Mays J, Marks D, Malawista SE.

N Engl J Med. 1998 Jul 23;339(4):216-22. Erratum in: N Engl J Med 1998 Aug 20;339(8):571.

19.

Inhibition of Borrelia burgdorferi-tick interactions in vivo by outer surface protein A antibody.

Pal U, Montgomery RR, Lusitani D, Voet P, Weynants V, Malawista SE, Lobet Y, Fikrig E.

J Immunol. 2001 Jun 15;166(12):7398-403.

20.

Inability of truncated recombinant Osp A proteins to elicit protective immunity to Borrelia burgdorferi in mice.

Bockenstedt LK, Fikrig E, Barthold SW, Kantor FS, Flavell RA.

J Immunol. 1993 Jul 15;151(2):900-6.

PMID:
8335917

Supplemental Content

Support Center